HEPA Archives - Page 7 of 11

Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...

December 29, 2020

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Developments

Hepion completes 75 mg CRV431 dosing, initiates 225 mg dosing in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) completed patient dosing in the 75 mg cohort of its Phase 2a ‘AMBITION’ clinical trial, which is evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). In...

December 10, 2020

Developments

Hepion reports CRV431 may reduce risk of NASH-associated ischemic stroke

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from a translational research study in which its lead drug candidate, CRV431, decreased formation of procoagulant platelets. The company noted that patients with...

December 2, 2020

Developments

DSMB approves continuation of Hepion’s Phase 2a NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that an independent data safety monitoring board (DSMB) approved the continuation of the company’s Phase 2a ‘AMBITION’ clinical trial to the next dose level cohort. After...

November 18, 2020

Developments

Hepion to present positive CRV431 findings at liver conference

Hepion Pharmaceuticals (NASDAQ:HEPA) will present positive findings from an expanded study of CRV431 at The Liver Meeting Digital Experience 2020 on Nov. 13. The poster presentation will review a study in which...

November 12, 2020

Developments

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) enrolled the last patient in the 75 mg cohort of its Phase 2 ‘AMBITION’ clinical trial evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to...

November 10, 2020

Feature

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...

November 10, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 demonstrated positive activity against SARS-CoV-2 in a preclinical study conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Conducted under...

September 17, 2020

Tag - HEPA

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

Hepion completes 75 mg CRV431 dosing, initiates 225 mg dosing in AMBITION trial

Hepion reports CRV431 may reduce risk of NASH-associated ischemic stroke

DSMB approves continuation of Hepion’s Phase 2a NASH trial

Hepion to present positive CRV431 findings at liver conference

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

General

More